| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Allergy |
| Manuscript Type |
Case Report |
| Article Title |
Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N D'Alessandro-Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C Gabazza and Hidenori Ibata |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Esteban C Gabazza, MD, PhD, Director, Full Professor, Department of Immunology, Mie University School of Medicine, Mie University, Edobashi 2-174, Tsu 514-8507, Japan. gabazza@doc.medic.mie-u.ac.jp |
| Key Words |
Allergic bronchopulmonary aspergillosis; Dupilumab; asthma; Interleukin-13; Interleukin-4; Case report |
| Core Tip |
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to antigen from Aspergillus species that causes exacerbation of bronchial asthma, eosinophilic pneumonia, and bronchiectasis. Conventional therapy includes the administration of oral glucocorticoids and other antiasthmatic therapy. However, there are intractable cases showing repeated clinical exacerbations of bronchial asthma despite therapy with oral glucocorticoids. Previous reports have shown that the addition of monoclonal antibodies against interleukin (IL)-4/IL-13 or dupilumab to the treatment is effective and allows the reduction in the dose of glucocorticoids in ABPA patients. However, there is no report of complete withdrawal of oral glucocorticoids after therapy with dupilumab in these patients. Here, we report the first case of ABPA in which complete withdrawal of oral glucocorticoid was possible after treatment with dupilumab. |
| Publish Date |
2021-08-05 14:37 |
| Citation |
Nishimura T, Okano T, Naito M, Tsuji C, Iwanaka S, Sakakura Y, Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, Oomoto Y, Kobayashi T, Gabazza EC, Ibata H. Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report. World J Clin Cases 2021; 9(23): 6922-6928 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i23/6922.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i23.6922 |
